Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report) traded down 5.4% during trading on Monday . The company traded as low as $3.20 and last traded at $3.23. 537,059 shares changed hands during trading, a decline of 20% from the average session volume of 672,452 shares. The stock had previously closed at $3.41.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on CURLF shares. Needham & Company LLC reaffirmed a "buy" rating and set a $6.25 price target on shares of Curaleaf in a report on Thursday, August 8th. Cormark upgraded Curaleaf from a "hold" rating to a "moderate buy" rating in a research note on Monday, August 12th.
Get Our Latest Analysis on Curaleaf
Curaleaf Stock Performance
The stock has a market cap of $2.09 billion, a price-to-earnings ratio of -8.27 and a beta of 0.84. The company has a current ratio of 1.09, a quick ratio of 0.50 and a debt-to-equity ratio of 0.83. The firm has a fifty day simple moving average of $3.02 and a 200-day simple moving average of $3.93.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.01). The firm had revenue of $342.29 million for the quarter, compared to the consensus estimate of $344.57 million. Curaleaf had a negative return on equity of 14.75% and a negative net margin of 18.59%. Analysts forecast that Curaleaf Holdings, Inc. will post -0.24 EPS for the current fiscal year.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
